Literature DB >> 11718503

Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review.

A L Kwa1, V H Tam, M J Rybak.   

Abstract

Rhodococcus equi is a facultative, intracellular, gram-positive coccobacillus increasingly reported as an opportunistic pathogen in patients positive for human immunodeficiency virus (HIV). An HIV-positive man developed R. equi pneumonia and sepsis. He failed to improve despite surgical drainage of localized infection and many empiric antibiotics. Time-kill studies of R. equi isolated from the patient were performed against various antimicrobial agents to optimize therapy. Levofloxacin seemed to offer excellent in vitro bactericidal activity. Antagonism was observed with certain antibiotic combinations. Our anecdotal case report suggests that fluoroquinolones such as levofloxacin may offer superior efficacy to standard therapy in rhodococcal infections; their clinical utility deserves further investigation. In view of potential antagonism, prospective susceptibility testing for various drugs and drug combinations should be considered when clinically indicated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11718503     DOI: 10.1592/phco.21.11.998.34512

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  Cavitary Rhodococcus equi pneumonia with endobronchial granulomas: report of an unusual case.

Authors:  S A Fidvi; A R Brudnicki; M I Chowdhury; D Beneck
Journal:  Pediatr Radiol       Date:  2002-12-10

2.  Tuberculosis with cavities? Rapid diagnosis of Rhodococcus equi pulmonary infection with cavities by acid-fast staining: A case report.

Authors:  Yuhang Jiang; Jian Li; Weichao Qin; Yuan Gao; Xin Liao; Yan Zeng
Journal:  Front Public Health       Date:  2022-09-16

3.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.